96 results
Page 3 of 5
8-K
nfds3jl
7 Apr 20
Departure of Directors or Certain Officers
8:01am
8-K
EX-10.1
j4tl5lupn erhy3je
12 Mar 20
Sientra Announces $60 Million Convertible Notes Investment from
4:40pm
8-K
EX-99.1
ld953oloxc v3i
13 Jan 20
Sientra Announces Preliminary Unaudited 4Q19 Net Sales
5:25pm
8-K
EX-10.1
8qg9m
7 Nov 19
Entry into a Material Definitive Agreement
4:38pm
8-K
EX-10.2
2degpnmz
7 Nov 19
Entry into a Material Definitive Agreement
4:38pm
8-K/A
EX-99.1
0ma87vwl hmupg0ilp6
9 Aug 19
Sientra Reports Second Quarter 2019 Financial Results
4:25pm
8-K
EX-99.1
s6nkthr
8 Aug 19
Sientra Reports Second Quarter 2019 Financial Results
4:21pm
8-K
EX-1.1
5s9 2ncedpwmy
5 Jun 19
Sientra Commences Public Offering of Common Stock
4:10pm
424B5
ma0e2 kfl2pu58
5 Jun 19
Prospectus supplement for primary offering
4:03pm
424B5
7lai4kb
3 Jun 19
Prospectus supplement for primary offering
4:01pm
8-K
EX-99.1
i0dx76gh
21 Mar 19
Sientra® Issues Statement in Response to FDA Post-Approval Study Warning Letter
4:40pm
8-K
EX-99.1
09jrxrmkwtklxcexz0t
12 Mar 19
Sientra Reports Fourth Quarter and Full Year 2018 Financial Results
4:31pm